Literature DB >> 16421007

Helicobacter pylori-associated immune thrombocytopenia.

Massimo Franchini1, Dino Veneri.   

Abstract

Idiopatic thrombocytopenic purpura (ITP), a disorder characterized by autoantibody-mediated platelet destruction, may be primary or secondary to various illnesses including lymphoproliferative, autoimmune, or infectious diseases. There are increasing data on the association between Helicobacter pylori infection and idiopathic thrombocytopenic purpura and the significant increase in platelet count after bacterial eradication. The aim of this review is to consider the studies so far published on Helicobacter pylori infection and idiopathic thrombocytopenic purpura in order to evaluate a possible pathogenic correlation between these two conditions. A review of the literature data show that Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura is effective in increasing platelet count in approximately half of the cases. However, since the studies so far published are few, sometimes controversial and involve small series of patients, further controlled studies on larger numbers of patients with longer follow-up are needed to confirm these preliminary findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421007     DOI: 10.1080/09537100500438057

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  12 in total

Review 1.  Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography.

Authors:  Galit H Frydman; Nick Davis; Paul L Beck; James G Fox
Journal:  Helicobacter       Date:  2015-03-01       Impact factor: 5.753

Review 2.  Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies.

Authors:  Masataka Kuwana; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

Review 3.  Extragastric diseases associated with Helicobacter pylori infection.

Authors:  Karen J Goodman; Stephanie L Joyce; Kathleen P Ismond
Journal:  Curr Gastroenterol Rep       Date:  2006-12

4.  Production of autoantibodies by murine B-1a cells stimulated with Helicobacter pylori urease through toll-like receptor 2 signaling.

Authors:  Fumiko Kobayashi; Eri Watanabe; Yohko Nakagawa; Shingo Yamanishi; Yoshihiko Norose; Yoshitaka Fukunaga; Hidemi Takahashi
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

5.  Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States.

Authors:  Hashem B El-Serag; John Y Kao; Fasiha Kanwal; Mark Gilger; Frank LoVecchio; Steven F Moss; Sheila E Crowe; Adam Elfant; Thomas Haas; Ronald J Hapke; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-17       Impact factor: 11.382

Review 6.  Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms.

Authors:  Masataka Kuwana
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 7.  Helicobacter pylori infection: new pathogenetic and clinical aspects.

Authors:  Krisztina Hagymási; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

8.  Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients.

Authors:  Atsuko Asahi; Tetsuya Nishimoto; Yuka Okazaki; Hidekazu Suzuki; Tatsuhiro Masaoka; Yutaka Kawakami; Yasuo Ikeda; Masataka Kuwana
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

9.  Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset.

Authors:  Adi Aran; Ling Lin; Sona Nevsimalova; Giuseppe Plazzi; Seung Chul Hong; Karin Weiner; Jamie Zeitzer; Emmanuel Mignot
Journal:  Sleep       Date:  2009-08       Impact factor: 5.849

10.  Helicobacter pylori Infection and Upper Gastrointestinal Disorders.

Authors:  Vikram Kate; Nanda K Maroju; N Ananthakrishnan
Journal:  Gastroenterol Res Pract       Date:  2013-07-30       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.